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1. Introduction 
Several radioimmunoassays for prostaglandins have 
been developed recently [1-6]. Using these methods 
analyses of concentrations of primary prostaglandins 
in peripheral venous blood, in particular PGF2a**, 
have been carried out. However, the endogenous le- 
vels of PGF2a obtained have not been verified by 
other methods. Studies on the production rate of 
PGF2a under normal conditions and of plasma pro- 
staglandins in humans during continuous infusion of 
PGF2a have recently been reported [7-9].  The data 
from these mass spectrometric studies indicated that 
the reported endogenous plasma levels of PGF2a ob- 
tained by radioimmunoassay might be by far too high. 
It was also recently demonstrated that PGE 2 and 
PGF2a administered intravenously are rapidly con- 
verted into 1 lo~-hydroxy-9, 15-diketoprost-5-enoic 
acid and 9a, 1 lct-dihydroxy-15-ketoprost-5-enoic 
acid, respectively [ 10, 11 ]. The mass spectrometric 
studies referred to above also showed that the latter 
keto-metabolite occurs in plasma in 20-30-fold high- 
er concentration than the administered PGF2` . . It 
therefore seems that monitoring of PGF2a production 
might best be achieved by measuring the keto meta- 
bolite in plasma. An additional reason for this ap- 
proach is that extensive conversion of prostaglandins 
to 15-keto-13, 14-dihydroderivatives occurs in many 
tissues. 
The present report describes the development of a 
radioimmunoassay for9a, 1 lt~-dihydroxy- 15-keto- 
prost-5-enoic acid. The method has been evaluated by 
quantitative mass spdctrometry using the deuterium 
* Present address: Department ofChemistry, Karolinska In- 
stitutet, S-104 01 Stockholm 60, Sweden. 
carrier technique [ 12]. 
2. Experimental 
[9/~-3H]9t~, 1 la-Dihydroxy-15-ketoprost-5-enoic 
acid, 10 mg, specific activity 0.2 mCi/mmole, was 
prepared by incubation of [9/~-3H]PGF2a with the 
high speed supernatant from a swine kidney homo- 
genate [13]. [17, 18-3H219a, 1la-Dihydroxy-15- 
ketoprost-5-enoie acid, 70/aCi, specific activity, about 
50 Ci/mmole, was prepared in the corresponding way 
from [17, 18-3H2]PGF2`*, obtained as described ear- 
lier [14]. 
Ten mg of [9/~-3H]9t~, 1 let-dihydroxy-15-keto- 
prost-5-enoic acid was coupled with 40 mg of bovine 
serum albumin in the presence of 10 mg of I-ethyl- 
3 (3-dimethylamlnopropyl) carbodiimide [3]. By 
analysis of the tritium content of a small amount of 
the dialyzed and lyophilized material it was estab- 
lished that approx. 9 molecules of the prostaglandin 
metabolite was coupled to each BSA molecule. 
The conjugate was dissolved in distilled water to 
a concentration f 5 mg/ml and was emulsified with 
an equal volume of Freund's complete adjuvant. Two 
rabbits were injected subcutaneously with the emul- 
** Abbreviations: 
Prostaglandin F2a (PGF2h): 9% 11`*, 15-trihydroxyprosta- 
5, 13-dienoic acid; prostaglandin E2 (PGE2): 11a, 15-di- 
hydroxy-9-ketoprosta-5, 13-dienoic acid; prostaglandin 
FI,. (PGFI,~): 9,*, lla, 15-trihydroxyprost-13-enoic acid; 
prostaglandin E l (PGEI): 11`*, 15-dihydroxy-9-ketoprost- 
13-enoic acid; prostaglandin A 2(PGA2): 15-hydroxy-9- 
ketoprosta-5, 10, 13-trienoic a id; prostaglandin B2 
(PGB2): 15-hydxoxy-9-ketoprosta-5, 8 (12), 13-trienoic 
acid; BSA: bovine serum albumin. 
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sion along the flank area once a week for four weeks. 
Two weeks after the last injection the animals were 
bled for the first time and then at weekly intervals. 
A detectable antibody titer was present in both cases 
at the first bleeding. The highest iters were obtained 
10-12 weeks after beginning of the immunization, 
after which the titers gradually declined. 
Anti-rabbit 7-globulin antibodies were simultane- 
ously generated in a goat which was given weekly 
subcutaneous injections of rabbit 7-globulin for four 
weeks and then at monthly intervals. 
The assay was carried out as follows: To 0.5 ml of 
a rabbit serum dilution (a dilution of 1 : 1000 gave a 
65% binding of added 3H-labelled compound) were 
added 0.1 ml of prostaglandin standard or sample 
and 0.1 ml of [17, 18-3H219a , 1 la-dihydroxy-15- 
ketoprost-5-enoic a id (about 10,000 cpm). All solu- 
tions were made in 0.05 M Tris buffer, pH 7.8. After 
3 hr at room temp. 0.1 ml of a 1:10 dilution of goat 
anti-rabbit 7-globulin serum was added and the tubes 
were kept for 12 hr at +4 °. The formed precipitate 
was removed by centrifugation and 0.5 ml of the 
clear supernatant was assayed for radioactivity. 
Serum samples, 0.5 ml, were extracted once with 
0.5 ml of pentane, which was discarded, and subse- 
quently acidified to pH 3 with 1 N HCI and extracted 
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Fig. 1. Specificity of 9c~, 1 ia-dihydroxy-15-ketoprost-S-enoic 
acid antiserum. C6mpounds tested were: (1) 9a, 1 lordihy- 
droxy-15-ketoprost-5-enoic ac d (15-dehydro-13, 14-dihydro- 
PGF2~; (2) 9a, 1 la-dihydroxy-15-ketoprosta-5, 13-dienoic 
acid (15-dehydro-PGF2a); (3) 9a, 1 Its, 15-trihydroxyprost- 
5-enoic acid (13, 14-dihydro-PGF2~); (4) PGF2a; (5) 
PGFla;(6) PGE2;(7) PGEI;(8) PGA2;(9) PGB 2. 
twice with 1 ml of ethyl acetate. The combined ethyl 
acetate phases were washed once with 1 ml of water 
and evaporated to dryness. The residue was taken up 
in 0.5 ml of 0.05 M Tris buffer, pH 7.8. Prior to ex- 
traction of the serum sample a small amount of [17, 
18-3H219a, 1la-dihydroxy-15-ketoprost-5-enoic 
acid was added, and thus the recovery of the com- 
pound could be measured (generally 75-85%). 
3. Results and discussion 
Standard curves obtained with the method des- 
cribed above showed significant differences between 
50 and 100 picograms of the compound (fig. 1). 
When other prostaglandins or prostaglandin meta- 
bolites were used to replace the unlabeUed compound 
in the assay, the antiserum was found to cross-react 
to some extent only with 9t~, 1 la-dihydroxy-15- 
ketoprosta-5, 13-dienoic acid, 9a, 1 l t~, 15-trihydroxy- 
prost-5-enoic acid, and PGF2a (fig. 1 and table 1). 
Table 1 
Specificity of antiserum directed against 9~, 1 la-dihydro~ty- 
15-ketoprost-5-enoic acid. 
Prostaglandin 
Picogramg required 
to displace 50% of Relative 
bound 3H-9tx, lla- cross re- 
dihydroxy-15-keto- action (%) 
prost-5-enoic acid 
9,*, 1 la-dihydroxy- 
15-ketoprost-5-enoic 
acid (15-dehydro-13, 
14-dihydro-PGF2a) 600 100.0 
15-Dehydro-PGF2a 16,000 3.8 
13, 14-Dihydro- 
PGF2~ 24,000 2.5 
PGF2t x 90,000 0.7 
PGF 1 a 280,000 0.2 
PGE 2 >500,000 < 0.1 
PGE l >500,000 < 0.1 
PGA 2 >500,000 < 0.1 
PGB 2 >500,000 < 0.1 
The assay was carried out as described in the Experimental 
section. 
Structural alterations in the ring were easily recog- 
nized by the antiserum. 
Serum samples that were analyzed for concentra- 
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tions of 9or, 1 lo~-dihydroxy-15-ketoprost-5-enoic 
acid with this method were purified only by extrac- 
tion and were not subjected to separation i to dif- 
ferent classes of prostaglandins bychromatographic 
procedures, due to the low degree of cross reactivity 
with compounds of the E-type and also with PGFln 
and PGF2a. 9or, 11 t~-Dihydroxy- 15-ketoprost-5-enoic 
acid has been shown to be by far the most abundant 
metabolite of PGF2a in serum, and other metabolites 
of PGF2a are therefore not likely to interfere appre- 
ciably with the assay. 
Table 2 shows the results obtained in an experi- 
Table 2 
Radioimmunoassay of known amounts of 9a, 1 la-dihydroxy- 
15-ketoprost-5-enoic ac dadded to serum from a female sub- 
ject. 
Amount added (ng) Serum level Mean -+ SD 
per ml of serum measured (ng/ml) 
were given PGF2a by intravenous infusion for several 
hours. Serum samples were collected prior to admin- 
istration and after 3 hr of infusion, and these samples 
were extracted and analyzed by radioimmunoassay 
as described above. 
The preinfusion values were in all cases less than 
0.5 ng/ml serum using both methods. A comparison 
between the analyses of the three-hour samples i  
shown in fig. 2. As can be seen, the results obtained 
by the two methods compare favourably, however, 
the radioimmunoassay v lues were consistently some- 
what lower. 
The radioimmunoassay described thus provides 
for the first time a rapid and accurate method for 
analysis of the major metabolite of PGF2~, 9or, 1 h~- 
dihydroxy- 15-ketoprost-5-enoic acid, in:large num- 
bers of plasma or serum samples. This will be of im- 
portance for studies of the physiological role of 
PGF2a and also for pharmacokinetic studies. 
0 0 
0 0.24 
0.20 0.28 
0.20 0.34 
0.80 0.78 
0.80 0.88 
3.20 3.48 
3.20 3.02 
12.80 13.80 ~ 
12.80 13.60 |
12.80 12.80 ~ 
I2.80 13.20 /
12.80 14.40 ]
12.80 14.20 
25.60 23.60 
25.60 28.40 
13.66 +- 1.04 
ment where known amounts of 9t~, 1 lmdihydroxy- 15- 
ketoprost-5-enoic acid were added to serum samples 
from a female subject prior to extraction. The ob- 
tained values have been corrected for recovery in each 
case. The concentration f the metabolite in serum 
prior to addition of the compound was 0-0.24 ng/ml 
according to this experiment. Additional results on 
normal blood levels will be reported later. 
For a further evaluation results obtained with this 
method were in some cases compared with those ob- 
tained by a gas chromatographic-mass spectrometric 
method (based on addition of deuterium labelled 
carrier to the sample, cf. [8, 12, 15]. Six patients 
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Fig. 2. Comparison between quantitative mass pectrometry 
and radioimmunoassay for 9a, 1 la-dihydroxy-15-ketoprost- 
5-enoic acid. The serum samples were obtained from six pa- 
tients receiving intravenous infusion of PGF2t ~, 75 ~g/min. 
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